BusinessTESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual MeetingBy Nasdaq OMXSep 11, 2017, 12:01 PM UTC
BusinessNew Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune ResponseBy Nasdaq OMXSep 8, 2017, 8:00 AM UTC
BusinessTESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual MeetingBy Nasdaq OMXAug 25, 2017, 12:01 PM UTC
BusinessOncoMed Presents Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 CongressBy Nasdaq OMXOct 10, 2016, 12:30 PM UTC
BusinessTESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016By Nasdaq OMXOct 8, 2016, 6:15 AM UTC
BusinessAdaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXOct 5, 2016, 8:30 PM UTC
BusinessOncoMed to Present Clinical Data for Wnt Inhibitors at the ESMO 2016 CongressBy Nasdaq OMXSep 29, 2016, 12:31 PM UTC
BusinessOncoMed to Present Clinical Data for Wnt Inhibitors at the ESMO 2016 CongressBy Nasdaq OMXSep 29, 2016, 12:31 PM UTC
